| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/29/2006 | US20060142571 improved ability to inhibit the replication of mutant strains of drug or multidrug resistant HIV strains; Indene/benzofuran Substituted Pyrimidines |
| 06/29/2006 | US20060142569 Methods of synthesizing 3-amino-1,2-4-benzotriazines |
| 06/29/2006 | US20060142556 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| 06/29/2006 | US20060142398 Method and composition for adminstering an NMDA receptor antagonist to a subject |
| 06/29/2006 | US20060142397 Use of a pparalpha agonist and metormin for decreasing the serum triglycerides |
| 06/29/2006 | US20060142396 Use of GABA agonists for the treatment of spastic disorders, convulsions, epilepsy, and neuroprotection |
| 06/29/2006 | US20060142395 Modulation of intracellular calcium signaling by N-acylethanolamines |
| 06/29/2006 | US20060142394 Use of proteases for decomposing allergens |
| 06/29/2006 | US20060142393 Bis(thio-hydrazide amides) for treatment of hyperplasia |
| 06/29/2006 | US20060142392 Process for preparing (2s)-3-(4-{2-[amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid derivatives |
| 06/29/2006 | US20060142391 Ppargamma-activating pharmaceutical composition |
| 06/29/2006 | US20060142390 Treatment for severe melancholic depression |
| 06/29/2006 | US20060142389 Pharmaceutically useful salts of carboxylic acid derivatives |
| 06/29/2006 | US20060142388 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative |
| 06/29/2006 | US20060142387 Naphthylamine compounds such as N-(cyclopropylmethyl)-N-(4-nitro-1-naphthyl)-N-propylamine; selective androgen receptor modulators; osteoporosis, muscle wasting, frailty, cardiovascular disease, hormone-dependent cancers, dyslipidemia, menopausal vasomotor conditions, sexual disorders |
| 06/29/2006 | US20060142386 Bis(thio-hydrazide amides) for increasing Hsp70 expression |
| 06/29/2006 | US20060142385 Inhibitors of matrix metalloproteinase |
| 06/29/2006 | US20060142383 3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs |
| 06/29/2006 | US20060142382 Skin lightening composition |
| 06/29/2006 | US20060142380 oxidizing (4-Chloro-2-fluorophenoxy)-6-methyl-2-[4-(methylthio)phenyl]-4H-pyran-4-one with an oxidizer selected from sodim metaperiodate and a mixture of titanium teteraisoperoxide, tert-butyl hydroperoxide and diethyl tartrate; 3-(2,4-Difluorophenoxy)-6-methyl-2-[4-(methylsulfinyl)phenyl]-4H-pyran-4-one |
| 06/29/2006 | US20060142379 Use of AP-1 activators to treat glaucoma and ocular hypertension |
| 06/29/2006 | US20060142378 Amino-functionalized 1,2,4-trioxanes useful as antimalarial agents and process for preparation thereof |
| 06/29/2006 | US20060142377 water-soluble carboxylic acid dimers that are thermally stable and stable toward hydrolysis, less toxicity; plasmodium protozoan parasites; human malaria and Plasmodium falciparum; leukemia, lung, colon, central nervous system, ovarian, renal, prostate, and breast cancer, melanoma |
| 06/29/2006 | US20060142376 Preparing levetiracetam by deaminomethylation of the pure enantiomer intermediate: N-(dialkylamino- (or -pyrrolidinyl-, piperidinyl-, morpholinyl-, piperazinyl- or alkylpiperazinyl-)methyl)2-pyrrolidonylbutyramide or its acid addition salt |
| 06/29/2006 | US20060142375 Administering serotonin enhancer (e.g., a serotonin reuptake inhibitor) and concurrently administering 5-hydroxytryptophan to enhance the activity of the serotonin enahancer for therapy of unipolar major depression |
| 06/29/2006 | US20060142374 Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| 06/29/2006 | US20060142373 Medicaments for the Treatment or Prevention of Fibrotic Diseases |
| 06/29/2006 | US20060142372 For use as antidepressants, anxiolytics, antipsychotics, neuroleptics and/or antihypertonics, have actions on the central nervous system, in particular 5-HT reuptake-inhibiting actions, in that they influence serotoninergic transmission, they have a strong affinity to the 5-HT1A receptors |
| 06/29/2006 | US20060142371 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor |
| 06/29/2006 | US20060142370 Sumanene and method for manufacturing the same |
| 06/29/2006 | US20060142369 Delta 1-pyrrolines used as pesticides |
| 06/29/2006 | US20060142368 Compounds and methods for inducing apoptosis in proliferating cells |
| 06/29/2006 | US20060142366 Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 |
| 06/29/2006 | US20060142365 Benzimidazole compounds and antiviral uses thereof |
| 06/29/2006 | US20060142364 2-tert-Butyl-1-(cyclohexylmethyl)-N,N-bis(2,2,2-trifluoroethyl)-1H-benzimidazole-5-carboxamide; treating pain |
| 06/29/2006 | US20060142363 Imidazolidinedione analogs useful as anticoagulants and antithrombotics |
| 06/29/2006 | US20060142362 Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin |
| 06/29/2006 | US20060142361 Azole derivatives and methods for making the same |
| 06/29/2006 | US20060142360 Having a central trivalent nitrogen atom to which is attached either direct or indirectly three ring systems, at least one of which is substituted by a sulfamate group and one by a halogen; steroid sulfatase and aromatase inhibitors |
| 06/29/2006 | US20060142358 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes |
| 06/29/2006 | US20060142357 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 06/29/2006 | US20060142356 Novel therapeutic method and compositions for topical administration |
| 06/29/2006 | US20060142355 Carboxylic acid peri-substituted bicyclics for occlusive artery disease |
| 06/29/2006 | US20060142354 Use of epothilone derivatives for the treatment of hyperparathyroidism |
| 06/29/2006 | US20060142353 Cetylpyridinium diclofenac and its preparation by reacting a mineral or organic salt of diclofenac with cetylpyridinium halide or hydroxide in a solvent such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane, trichloroethane, tetrachloroethane, trichloroethylene and trichloropropane |
| 06/29/2006 | US20060142352 Compounds useful for the treatment of cancer, compositions thereof and methods therewith |
| 06/29/2006 | US20060142351 Method of increasing systemic tryptophan with niacin compounds |
| 06/29/2006 | US20060142350 prepared by coupling 2-(Butyl-1-sulfonylamino)benzoic acid with 1(R)-(6-methoxypyridin-3-yl)propylamine; drugs used for the therapy or prophylaxis of cardiovascular disorders; Antiarrhythmia agents |
| 06/29/2006 | US20060142349 Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
| 06/29/2006 | US20060142348 Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease |
| 06/29/2006 | US20060142347 Compounds and methods for the treatment or prevention of Flavivirus infections |
| 06/29/2006 | US20060142346 S-lansoprazole compositions and methods |
| 06/29/2006 | US20060142345 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| 06/29/2006 | US20060142344 Method for treating HIV infection through co-administration of tipranavir and GW695634 |
| 06/29/2006 | US20060142342 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| 06/29/2006 | US20060142341 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
| 06/29/2006 | US20060142340 improved metabolic stability; gastrointestinal conditions like hypermotility, irritable bowel syndrome (IBS), constipation or diarrhea; amidation |
| 06/29/2006 | US20060142339 gastrointestinal disorders hypermotility, irritable bowel syndrome, constipation or diarrhea |
| 06/29/2006 | US20060142338 Androgen sensitive diseases; prostate cancer; skin disorders; alopecia |
| 06/29/2006 | US20060142337 Piperidine derivative and use thereof |
| 06/29/2006 | US20060142336 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 06/29/2006 | US20060142335 Heptyl-carbamic acid 1-benzyl-1, 2, 3, 4-tetrahydro-quinolin-6-yl ester; Alzheimer's disease, senile dementia or memory disturbance |
| 06/29/2006 | US20060142334 Tetrahydroquinoline derivatives |
| 06/29/2006 | US20060142333 e.g. N-(1-Methyl-1,2,3,4-tetrahydroquinolin-7-yl)-1,1'-biphenyl-4-carboxamide; capsaicin recepor antagonist; analgesic; neuropathic, postoperative, postrheumatoid arthritic, back, cancer pain, neuralgia, dental pain, headache, migraine, diabetic and HIV-related neuropathy |
| 06/29/2006 | US20060142332 5-HT7 receptor antagonists |
| 06/29/2006 | US20060142331 of serotonin, dopamine and noradrenaline receptors; e.g. 2-(2,3-Dichlorophenoxymethyl)-8-methyl-3-(3-chlorophenyl)-8-aza-bicyclo[3.2.1]octane; antidepressant. anxiolytic agent; eating, bipolar disorders, obesity; drug, tobacco, alcohol abuse; neurodegenerative diseases |
| 06/29/2006 | US20060142330 e.g. 4-chloro-3-(phenylsulfonyl)-1-(piperidin-4-ylmethyl)-1H-pyrazolo[4,3-b]pyridineI; antidepressant, anxiolytic agent, cognition activator; Alzheimer's and attention deficit disorder, schizophrenia, obsessive compulsive disorders, |
| 06/29/2006 | US20060142329 Substituted fused N-heteroaryl compounds such as imidazo[1,5a]- or [1,2s]pyridines, e.g., 3-[3-(Pyrrolylphenoxy-2-hydroxypropyl)aminoalkyl]imidazo[1,5-a]pyridine derivatives, especially HCl salts; treating obesity and type 2 diabetes |
| 06/29/2006 | US20060142328 Beta 3 adrenergic agonists |
| 06/29/2006 | US20060142327 Beta 3 adrenergic agonists |
| 06/29/2006 | US20060142326 Use of pyrazolopyridines for the treatment of cognitive deficits |
| 06/29/2006 | US20060142325 Fused bicyclic-substituted amines as histamine-3 receptor ligands |
| 06/29/2006 | US20060142324 Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
| 06/29/2006 | US20060142323 Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease |
| 06/29/2006 | US20060142322 2-Alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9H-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents |
| 06/29/2006 | US20060142321 2-[1-(5-Chloro-2,4-difluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolinehydrochloride; antidepressant, anxiolytic, hypotensive agent; psychosis, schizophrenia, migraine, cognition activity; pharmacokinetics |
| 06/29/2006 | US20060142320 Polymorphic forms of naltrexone |
| 06/29/2006 | US20060142319 Pyridyl-substituted spiro-hydantoin crystalline forms and process |
| 06/29/2006 | US20060142318 eating disorders of disturbed fundus such as dyspepsia, early satiety, bloating, anorexia; fundic relaxation; 1-[1-[(2,3-dihydro[1,4]dioxino[2,3-b]pyridin-3-yl)methyl]-4-piperidinyl]-2-imidazolidinone; improved pharmacokinetics, less vasoconstriction, side effect reduction, sustain release |
| 06/29/2006 | US20060142317 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof |
| 06/29/2006 | US20060142316 synergistic mixtures of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, fluorouracil or irinocetan, for the treatment of cancers; angiogenesis inhibitors and vascular permeability reducing effect in mammals |
| 06/29/2006 | US20060142315 Substituted biaryl piperazinyl-pyridine analogues |
| 06/29/2006 | US20060142314 2-substituted-4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline compounds; use treating hypertension, atherosclerosis, restenosis, cerebral ischemia or vasospasm, neurodegeneration, spinal cord injury, cancer, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction |
| 06/29/2006 | US20060142313 2-substituted-4-(indazolamino)quinazoline compounds; use treating hypertension, atherosclerosis, restenosis, cerebral ischemia or vasospasm, neurodegeneration, spinal cord injury, cancer, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction |
| 06/29/2006 | US20060142312 C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| 06/29/2006 | US20060142311 Prodan-containing nucleotide and use thereof |
| 06/29/2006 | US20060142310 for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine |
| 06/29/2006 | US20060142309 8-Heteroaryl xanthine adenosine A2B receptor antagonists |
| 06/29/2006 | US20060142308 Synergistic combination comprising roflumilast and formoterol |
| 06/29/2006 | US20060142307 Controlling intraocular pressure |
| 06/29/2006 | US20060142306 Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents |
| 06/29/2006 | US20060142305 N- alpha -(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanine-4-ethoxycarbonylpiperazinium hydrogen sulfate; N- alpha -(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyguanidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide; urokinase plasminogen activator inhibitor; anticarcinogenic agent |
| 06/29/2006 | US20060142304 Method for treating or preventing pruritic and neurogenic skin disorders |
| 06/29/2006 | US20060142303 Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents |
| 06/29/2006 | US20060142302 Chemical compounds |
| 06/29/2006 | US20060142301 Substituted 1-benzyl-4-substituted piperazine analogues |
| 06/29/2006 | US20060142300 Anhydrous crystalline forms of I and II of 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1- piperazinyl) 4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (gatifloxacin) |
| 06/29/2006 | US20060142299 Crystalline aripiprazole solvates |
| 06/29/2006 | US20060142298 Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents |
| 06/29/2006 | US20060142297 Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine |